CureVac BV reports Q2 results

* CureVac BV press release [https://seekingalpha.com/pr/20202438-curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2025-and] (NASDAQ:CVAC [https://seekingalpha.com/symbol/CVAC]): Q2 Revenues amounted to €1.2 million (-92% Y/Y).
* The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licensing Agreement as well as lower sales to CRISPR Therapeutics.
* Pre-tax loss was €60.0 million

MORE ON CUREVAC BV

* BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer [https://seekingalpha.com/article/4794516-biontech-acquisition-of-curevac-brings-complementary-method-to-target-cancer]
* GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled [https://seekingalpha.com/news/4482370-gsk-curevac-settle-patent-dispute-with-pfizer-biontech]
* U.S. to phase out funding for mRNA vaccine development [https://seekingalpha.com/news/4479579-hhs-halts-funding-mrna-vaccine-activities]
* Seeking Alpha’s Quant Rating on CureVac BV [https://seekingalpha.com/symbol/CVAC/ratings/quant-ratings]
* Historical earnings data for CureVac BV [https://seekingalpha.com/symbol/CVAC/earnings]